Last reviewed · How we verify
NCT02343835
Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer
NA trial testing NanoKnife LEDC System in Pancreatic Cancer in 20 participants. Completed in 1 May 2021.
1 December 2020
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 January 2015 |
| Primary completion | 1 December 2020 |
| Estimated completion | 1 May 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- NanoKnife LEDC System
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Adults 18 to 80, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This protocol will study the impact of Irreversible electroporation (IRE) on immune response in patients diagnosed with unresectable pancreatic cancers smaller than 5.0 cm. It will profile the immune response to IRE of unresectable pancreatic cancers. The intra-tumoral and systemic immune response to IRE will be determined and compared to pre-ablated pancreatic cancer specimens and historical control specimens.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study.
Liu S, Qin Z, Xu J, Zeng J, et al · · 2019 · cited 21× · PMID 30863100 · DOI 10.2147/ott.s186721 -
Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma.
Lambin T, Lafon C, Drainville RA, Pioche M, et al · · 2022 · cited 13× · PMID 35645539 · DOI 10.3748/wjg.v28.i13.1288 -
Minimally invasive image-guided therapy of primary and metastatic pancreatic cancer.
Bibok A, Kim DW, Malafa M, Kis B. · · 2021 · cited 9× · PMID 34366607 · DOI 10.3748/wjg.v27.i27.4322 -
Are Aspects of Integrative Concepts Helpful to Improve Pancreatic Cancer Therapy?
Oei SL, Schad F. · · 2023 · cited 5× · PMID 36831465 · DOI 10.3390/cancers15041116 -
Prevention of Procedural Hypertension in the Irreversible Electroporation Ablation of Liver and Pancreatic Tumors Based on Distance from the Adrenal Gland.
Fang G, Niu L, Chen J. · · 2020 · cited 2× · PMID 32021424 · DOI 10.2147/cmar.s235227 -
Pulsed electric fields: a sharp sword in the battle against cancers.
Zhang L, Dong S, Teng F, Wang Y, et al · · 2025 · PMID 41357174 · DOI 10.3389/fimmu.2025.1682539
Verify or expand the search:
- PubMed search for NCT02343835
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of NanoKnife LEDC System
Trials testing the same drug.
- NCT02352935 — Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function · NA · completed
- NCT02340858 — Percutaneous Irreversible Electroportion for Unresectable Breast Cancer · NA · completed
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02343835 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 5 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02343835.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing